Todd Harrison - Humanity Has Had a 30,000 Year Relationship with Cannabis | #133

Episode Summary

Executive Summary: Todd Harrison argues cannabis is a once-in-a-generation investing theme driven by a long human history with the plant, emerging science around the endocannabinoid system, and major regulatory shifts. He sees opportunity across consumer products, biotech, and U.S. multi-state operators, emphasizing that public-market volatility and policy gaps create multiple arbitrages for patient investors.

Main Topics: Cannabis as a historical and scientific wellness theme (Priority: 5/5): Harrison frames cannabis as a long-standing human medicine with modern validation from endocannabinoid science, not simply a recreational drug. He ties societal acceptance to efficacy, PTSD experience, and medical use cases. Market bifurcation: consumer products vs. biotech medicine (Priority: 5/5): He argues the industry will split into a consumer/wellness side (beverages, nutraceuticals, topicals) and a biotech/pharma side focused on clinical indications like epilepsy, cancer, autism, and PTSD. The four arbitrages in cannabis investing (Priority: 5/5): Harrison outlines time vs. policy, price, perception, and liquidity as the central inefficiencies that investors can exploit as legalization and institutional adoption progress. Portfolio construction and volatility management (Priority: 4/5): He explains CB1 Capital’s approach: long-duration public-market investing, sizing positions carefully, using volatility to add or trim, and employing put strategies as downside buffers. Geographic opportunity set (Priority: 4/5): Canada is the most mature market, the U.S. is the largest near-term opportunity, and Australia plus select European/Latin American markets provide additional upside through underfollowed names. Identifying winners in a crowded ecosystem (Priority: 4/5): He argues only a small subset of the roughly 500 listed cannabis-related companies are real long-term winners, and that management quality, footprint, and institutional awareness will separate survivors from zombies. Education, transparency, and research coverage (Priority: 3/5): Harrison highlights Twitter, his firm’s recaps, and emerging sell-side coverage as key tools for investor education in a space still dominated by misinformation and thin research.

Key Arguments: Cannabis is not a new phenomenon; it has a 30,000-year relationship with humanity and was historically used as medicine. Modern acceptance is being driven by scientific understanding of the endocannabinoid system and proof points like FDA-approved CBD for epilepsy. The market should be viewed as a bifurcation between consumer wellness products and traditional biotech/medicine. Cannabinoids have distinct therapeutic profiles, so the space is broader than THC and CBD alone. Cannabis-friendly states showing 25% fewer opioid-related deaths supports the public-health case for legalization. The biggest investment edge comes from arbitrages in time, price, perception, and liquidity as policy catches up to science. U.S. multi-state operators and cannabis biotech offer the strongest upside, while Canada is more mature and Australia is underappreciated. Investors should expect extreme volatility and use position sizing, not concentration, to survive the frontier market dynamics. Only a minority of public cannabis names will become durable winners; many listed companies are likely to fail or consolidate. Institutional capital will eventually enter once banking, custody, and coverage improve, creating a major rerating opportunity.

Data Points: Human history with cannabis: 30,000 years - Harrison describes cannabis as having a long relationship with humanity, mainly through health and wellness. Time since endocannabinoid system discovery: Late 1980s to early 1990s - He notes Western medicine only recently discovered the body’s endocannabinoid system. FDA-approved CBD epilepsy drug: Epidiolex - He cites GW Pharmaceuticals’ purified CBD product as evidence of medical efficacy. Reduction in opioid deaths in cannabis-friendly states: 25% less - Used to support the public-health case for cannabis legalization. Estimated annual cannabis flower cash crop: $300 billion - He treats cannabis flower as an ingredient with massive optionality for downstream products. Potential future industry market cap: $2 to $3 trillion - His estimate for the eventual scale of the cannabis ecosystem as an ingredient-based market. Current global cannabis equities: About $50 billion - He contrasts present market capitalization with his long-term opportunity estimate. Positions in fund: About 30 - CB1 Capital’s global exposure across public markets and biotech. Position size range: 0.5% to 10% - He sizes small biotech positions around 0.5% and larger convictions up to 5%-6%, capped near 10%. Downside hedging allocation: 1% to 5% of assets - Used for non-correlated put strategies to buffer volatility. Listed companies tangential to cannabis: About 500 - He estimates only a subset are investable long-term businesses. Real companies worth owning: About 50 to 55 - His estimate of viable listed cannabis companies. U.S. operator race winners: Handful of $100 billion market caps - He predicts some U.S. cannabis operators could reach very large scale over 8-10 years. Revenue visibility: Billions of dollars in revenue next year - He expects the space to show major revenue recognition as markets mature. CBD consumer brands mentioned: Charlotte’s Web, Elixinol, Favidia - Examples of brands he sees benefiting from hemp/CBD demand. Banking reform timing expectation: First half of 2019 - His view on when U.S. cannabis banking reform would arrive. GW Pharma stock move: $180 to $123 - He cites the post-approval selloff in GW as evidence the market misunderstands the biotech opportunity. Corbus stock price: $6.50 to $7 - Example of a misunderstood cannabinoid biotech with analyst coverage and a large short interest. Corbus average price target: $23 - He notes analysts’ targets imply significant upside. Corbus short interest: 20-something percent - Used to illustrate skepticism and potential mispricing. Private-equity contribution example: 1 to 2 months early - He says private bridges can provide discounted entry ahead of public markets.

Pivotal Quotes: "“It’s not about getting high, it’s about getting well.”" — Todd Harrison: His trademarked framing of cannabis as a wellness and medical theme rather than a vice. "“We think there’s about 50, 55 companies that are actually real companies that we want to invest in.”" — Todd Harrison: He explains that most listed cannabis-related names are not durable businesses. "“Trading is the process of capturing the disconnect between perception and reality.”" — Todd Harrison: He describes his investing framework for a volatile, mispriced cannabis market.

Implications: The transcript suggests cannabis investing is a long-duration, policy-sensitive theme where winners will emerge slowly. Investors need discipline, selective research, and tolerance for volatility as institutional adoption and medical validation develop.